ey0017.11-13 | Pharmacologic Treatment | ESPEYB17
EA Day
, RJ Ford
, BK Smith
, P Mohammadi-Shemirani
, MR Morrow
, RM Gutgesell
, R Lu
, AR Raphenya
, M Kabiri
, AG McArthur
, N McInnes
, S Hess
, G Pare
, HC Gerstein
, GR Steinberg
To read the full abstract: Nat Metab 2019;1:12021208.Metformin has become a mainstay in the treatment of T2DM in over six decades of clinical use and is today one of the worlds most commonly prescribed drugs. Anti-diabetic properties of metformin rely on an inhibition of hepatic glucose output through AMPK-dependent, but also AMPK-independent effects (reviewed in (1)). Neverthel...